Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
March 09, 2023 16:05 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
March 02, 2023 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences Establishes New At-The-Market Facility
December 12, 2022 06:15 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
December 11, 2022 09:00 ET
|
Aptose Biosciences, Inc.
Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety and Efficacy Profile may Position Drug to...
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
December 07, 2022 16:05 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
November 14, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022
October 18, 2022 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral kinase...
Aptose to Participate in Cantor Oncology, Hematology & HemeOnc Conference
September 14, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.
September 13, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 30, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...